

Activity Tracking's Newest Companion Pulse Wave Velocity

Kathryn Sandberg, Stephen P. Wright, Jason G. Umans

See related article, pp 503–510

Chances are you or someone you know is wearing a device to monitor their physical activity. Sales of consumer physical activity monitor watches have skyrocketed from 15 million in 2014 to 65 million in 2017.¹ This explosion in physical activity monitoring is attracting investigators intrigued by their research potential.² Many consumer devices have the ability to transfer data on a scale that facilitates longitudinal studies. Once the validity of these consumer monitors was established for tracking steps, researchers began to use them in combination with devices to monitor other physiological functions. Brouard et al³ analyzed data from 19 000 adults who owned both a Withings Pulse activity tracker and the company's Food and Drug Administration–cleared wireless blood pressure (BP) cuff. The authors found increases of 1000 steps per day for 1 month led to decreases in systolic BP in both sexes (Δ Men, -0.13 mmHg; Δ Women, -0.21 mmHg). Using the same devices in >9000 individuals across 37 countries with an analysis stratified by body weight (BW), Menai et al⁴ found that increasing steps by >3000 per day decreased both systolic (-1.6 mmHg) and diastolic (-1.3 mmHg) BP in overweight but not in normal-weight individuals.

In this issue, Modena et al⁵ are the first to report findings from a study in a naturalistic setting that combines an activity tracker with a smart BW scale that also measures pulse wave velocity (PWV). Using ballistocardiography and impedance plethysmography, Withings was the first to develop a consumer device that measures PWV via a BW scale. Moreover, a recent report demonstrated acceptable comparability of these PWV measurements with values for carotid-femoral PWV assessed by applanation tonometry.⁶ The Modena study was conducted for 4 months in 246 adults who already owned all 3 Withings devices: a physical activity monitor watch, a BP cuff, and a smart scale. All 3 devices were connected to a custom-designed smartphone app.

As would have been predicted, PWV most strongly correlated with mean arterial pressure ($R^2=0.13$) and age ($R^2=0.20$) and was predicted by a combination of mean arterial pressure, age, BW, and heart rate ($R^2=0.36$) with only a weak association between steps per day and PWV ($R^2=0.02$). So, have we learned anything new about PWV? The answer is no. We already knew that PWV is inversely associated with physical activity and positively associated with BP, BW, and age and apparently correlated with heart rate.⁷ The question, however, is not “Have we learned anything new?” but rather “Can we learn anything new?” This study suggests, yes, we can. Not only have Modena et al⁵ demonstrated the ability to integrate 3 interconnected mobile health (mHealth) technologies for several months but they also have provided evidence the integrated data are valid, thereby opening the door to assessing interrelationships of cardiovascular disease risk factors, including sedentary lifestyle, dysregulated sleep, and elevated BP, heart rate, BW, body mass index, and PWV.

One key advantage of these consumer devices is their relative ease of use for cost- and resource-efficient longitudinal data collection in an ecologically valid setting. This enabled Kim et al⁸ to analyze BP variability in >55 000 individuals from 185 countries during 14 months, revealing that BP variability was associated with age, higher in women, and influenced by the time of day, day of the week, and geographical location. It remains unknown whether integrating PWV measurement would add value to a similar analysis of multiple cardiovascular risk factors.

Arterial stiffness, assessed by aortic PWV, is a strong predictor of cardiovascular disease and death.⁹ Thus, the ability to measure PWV at home opens the door to answering a myriad of questions concerning this risk factor. Large population studies of PWV could provide reference values to inform our understanding of arterial stiffness, guide individualized interventions, and disentangle lifestyle and other factors that contribute to the heterogeneity in BP and PWV interrelationships. Moreover, this technology would facilitate future research into new therapeutic strategies that might target PWV selectively.⁹

As with any approach, there are limitations that must be considered. The authors had no trouble recruiting participants in this proof-of-concept study; however, their population was highly skewed because only people who already owned all 3 devices, and who were also using the BP cuff at least once per week, for most weeks, and for 3 months before enrollment, were recruited. Would recruitment, retention, and study adherence be as effective in a population of greater research interest and representative of patients who might derive the greatest benefit from mHealth-guided risk factor assessment, diagnosis, lifestyle, and other individualized interventions?

The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

From the Georgetown-Howard Universities Center for Clinical and Translational Science, Georgetown University, Washington, DC (K.S., S.P.W., J.G.U.); and MedStar Health Research Institute, Hyattsville, MD (J.G.U.).

Correspondence to Kathryn Sandberg, Georgetown-Howard Universities Center for Clinical and Translational Science, Georgetown University, Suite 232 Bldg D, 4000 Reservoir Rd, NW Washington, DC 20008. E-mail sandberg@georgetown.edu

(*Hypertension*. 2018;72:294-295.)

DOI: 10.1161/HYPERTENSIONAHA.118.11276.)

© 2018 American Heart Association, Inc.

Hypertension is available at <http://hyper.ahajournals.org>

DOI: 10.1161/HYPERTENSIONAHA.118.11276

Our ongoing study using similar Withings devices in an urban black population with systolic BP between 130 and 160 mmHg suggests not.¹⁰ Of the 38 participants who have thus far completed the study, participation (defined as any data that month) and full adherence (9 BP cuffs and 9 scale measurements; 27 days of watch data) was at least 90% in the first month but declined substantially during 6 months for all 3 devices. Adherence (including failure to get a reading because of technical problems) was the greatest for daytime use of the activity monitor and the least for PWV measurement.

Although the consumer mHealth technology used in the Modena study holds much promise as a measurement tool, major challenges remain. Measuring PWV via the smart scale can be finicky at times requiring multiple attempts before a reading is generated. Validity and reliability of BP measurements remain a concern for all automated oscillometric devices, including the Withings BP-800, requiring comparison with auscultated measurements in individual participants or patients. Although total sleep time determined by the Withings Activité watch was validated by polysomnography, this device, similar to other consumer monitors, does not accurately assess sleep efficiency or sleep architecture, each of which predict health outcomes better than total sleep duration.¹¹ Additional challenges include changes in technology ownership, impacting device support and availability. Case in point, Withings was sold to Nokia in June 2016, and in January 2018, Nokia removed the PWV feature from the Withings scale through a mandatory software update. Hopefully, the recent buyback of the Nokia Digital Health business by a Withings cofounder¹² will lead to the reintroduction of the PWV feature on the smart scale and promote research on PWV in populations of interest.

Incorporating consumer monitors into behavior change research is a growing area of investigation. These devices coupled with notification systems that target the individual or social support group through mobile apps are being studied to determine what combinations of strategies are the most effective in creating behavior change, including motivating individuals to seek healthy lifestyles, promoting adherence to individualized prescription plans, and encouraging them to discuss their health with their physician. Investigators also need to focus on strategies to maintain participant engagement given that novelty of device use can fade with time and negatively impact study adherence.¹³

Another area of mHealth technology ripe for investigation is in health services; how could the use of mHealth technology influence healthcare costs and utilization? Will insurance claims be influenced by monitoring interventions and health self-management? Additional mHealth technologies (eg, continuous glucose monitoring, measurement of hemoglobin, oxygen saturation, body temperature, cardiac rhythm, or heart rate variability by electrocardiography or photoplethysmography) will further inform human health and impact models of clinical care. Moreover, improvements in technology that lead to reliable estimates of energy expenditure and detect the type

of physical activity (eg, running versus biking) will enable individualized prescriptions of physical activity regimens at a granular level. In conclusion, much more research is needed to achieve the full potential of wearable monitors as health interventions and opportunities for clinical research. Modena et al⁴ provide the encouragement to “Just do it.”

Sources of Funding

This work was supported by grants from the National Institutes of Health: TL1-TR-001431 (S.P. Wright), UL1-TR-001409 (K. Sandberg, S.P. Wright, and J.G. Umans), and R01-HL-119380 (K. Sandberg).

Disclosures

None.

References

1. Statista. The Statistics Portal. Global Wearable Technology Sales by Category From 2014 to 2018 (in Million Units). <https://www.statista.com/statistics/461548/wearable-techsales-worldwide-by-category/>. Accessed May 14, 2018.
2. Wright SP, Hall Brown TS, Collier SR, Sandberg K. How consumer physical activity monitors could transform human physiology research. *Am J Physiol Regul Integr Comp Physiol*. 2017;312:R358–R367. doi: 10.1152/ajpregu.00349.2016.
3. Brouard B, Chieh A, Lelong H, Menai M. LB01.09: study of a large cohort of connected devices users to assess the association between walking and blood pressure. *J Hypertens*. 2015;33(suppl 1):e47. doi: 10.1097/01.hjh.0000467471.36578.0d.
4. Menai M, Brouard B, Vegreville M, Chieh A, Schmidt N, Oppert JM, Lelong H, Loprinzi PD. Cross-Sectional and longitudinal associations of objectively-measured physical activity on blood pressure: evaluation in 37 countries. *Health Promot Perspect*. 2017;7:190–196. doi: 10.15171/hpp.2017.34.
5. Modena BD, Bellahsen O, Nikzad N, Chieh A, Parikh N, Dufek DM, Ebner G, Topol EJ, Steinhubl S. Advanced and accurate mobile health tracking devices record new cardiac vital signs. *Hypertension*. 2018;72:503–510. doi: 10.1161/HYPERTENSIONAHA.118.11177.
6. Campo D, Khettab H, Yu R, Genain N, Edouard P, Buard N, Boutouyrie P. Measurement of aortic pulse wave velocity with a connected bathroom scale. *Am J Hypertens*. 2017;30:876–883. doi: 10.1093/ajh/hpx059.
7. Tan I, Butlin M, Liu YY, Ng K, Avolio AP. Heart rate dependence of aortic pulse wave velocity at different arterial pressures in rats. *Hypertension*. 2012;60:528–533. doi: 10.1161/HYPERTENSIONAHA.112.194225.
8. Kim KI, Nikzad N, Quer G, Wineinger NE, Vegreville M, Normand A, Schmidt N, Topol EJ, Steinhubl S. Real world home blood pressure variability in over 56,000 individuals with nearly 17 million measurements. *Am J Hypertens*. 2018;31:566–573. doi: 10.1093/ajh/hpx221.
9. Fok H, Cruickshank JK. Future treatment of hypertension: shifting the focus from blood pressure lowering to arterial stiffness modulation? *Curr Hypertens Rep*. 2015;17:67. doi: 10.1007/s11906-015-0569-6.
10. Wright SP, Pollner EJ, Li X, Umans JG, Taylor TR, Williams CD, Clarke-Tasker V, Sandberg K. Ecological continuous assessment (ECA) of physical activity (PA) and sleep, and ecological momentary assessment (EMA) of blood pressure (BP), body weight (BW), and pulse wave velocity (PWV) in an urban black population. *ACTS*. 2018. <https://itunes.apple.com/us/app/translational-science-meeting/id1215061868?mt=8>.
11. Mantua J, Gravel N, Spencer RM. Reliability of sleep measures from four personal health monitoring devices compared to research-based actigraphy and polysomnography. *Sensors (Basel)*. 2016;16:E646.
12. Collins K. Nokia to sell Withings Health Division Back to Original Founder. *CNet*. <https://www.cnet.com/news/nokia-to-sell-withings-health-division-back-to-original-founder/>. Accessed May 14, 2018.
13. Sullivan AN, Lachman ME. Behavior change with fitness technology in sedentary adults: a review of the evidence for increasing physical activity. *Front Public Health*. 2016;4:289. doi: 10.3389/fpubh.2016.00289.

Activity Tracking's Newest Companion: Pulse Wave Velocity
Kathryn Sandberg, Stephen P. Wright and Jason G. Umans

Hypertension. 2018;72:294-295; originally published online July 2, 2018;
doi: 10.1161/HYPERTENSIONAHA.118.11276

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2018 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the
World Wide Web at:

<http://hyper.ahajournals.org/content/72/2/294>

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Hypertension* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

Reprints: Information about reprints can be found online at:
<http://www.lww.com/reprints>

Subscriptions: Information about subscribing to *Hypertension* is online at:
<http://hyper.ahajournals.org/subscriptions/>